share_log

First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma Announced Expansion of Adrulipase Intellectual Property Portfolio

第一波生物製藥宣佈擴大相關知識產權組合
Benzinga Real-time News ·  2023/01/25 07:08

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced today the company has filed a U.S. Provisional Patent application involving composition of matter improvements designed to enhance adrulipase's delayed release profile. This filing adds to the growing intellectual property (IP) portfolio governing adrulipase, which includes patent applications governing adrulipase formulation and methods of use and the utilization of enteric formulations in the delivery of adrulipase.

第一波生物製藥股份有限公司 (NASDAQ: FWBI) 今天宣佈,該公司已提交美國臨時專利申請,其中涉及物質改進的組成改進,旨在增強腺脂酶的延遲釋放輪廓。該文件增加了管理 adrulipase 的不斷增長的知識產權(IP)組合,其中包括管理 adrulipase 配方和使用方法以及腸溶配方在 adrulipase 交付中利用的專利申請。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論